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Abstract Mutations in the TARDBP gene are a cause of
autosomal dominant amyotrophic lateral sclerosis (ALS)
and of frontotemporal lobar degeneration (FTLD), but they
have not been found so far in patients with Parkinson’s
disease (PD). A founder TARDBP mutation (p.Ala382Thr)
was recently identified as the cause of ~30% of ALS cases
in Sardinia, a Mediterranean genetic isolate. We studied 327
consecutive Sardinian patients with clinically diagnosed PD
(88 familial, 239 sporadic) and 578 Sardinian controls. One
family with FTLD and parkinsonism was also included.
The p.Ala382Thr heterozygous mutation was detected in
eight unrelated PD patients (2.5%). The three patients from
the FTLD/parkinsonism family also carried this mutation.
Within the control group, there were three heterozygous
mutation carriers. During follow-up, one of these individ-
uals developed motoneuron disease and another, a rapidly
progressive dementia; the third remains healthy at the age
of 79 but two close relatives developed motoneuron disease
and dementia. The eight PD patients carrying the p.
Ala382Thr mutation had all sporadic disease presentation.
Their average onset age was 70.0 years (SD 9.4, range 51–
79), which is later but not significantly different from that
of the patients who did not carry this mutation. In
conclusion, we expand the clinical spectrum associated
with TARDBP mutations to FTLD with parkinsonism
without motoneuron disease and to clinically definite PD.
The TDP-43 protein might be directly involved in a broader
neurodegenerative spectrum, including not only motoneu-
ron disease and FTLD but also PD.
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Introduction
The identification of the “transactive response (TAR) DNA-
binding protein-43” (TDP-43) as the main component of
the pathological lesions in patients with frontotemporal
lobar degeneration (FTLD) with ubiquitin-positive inclu-
sions, in those with amyotrophic lateral sclerosis (ALS),
and in FTLD with motoneuron disease (FTLD-MND)
provided strong support to the contention that these
seemingly different diseases represent different parts of
one neurodegenerative spectrum [1]. Soon thereafter,
missense mutations in the gene encoding the TDP-43
protein (TARDBP) were identified in patients with autoso-
mal dominant ALS [2, 3] and, albeit more rarely, in patients
with FTLD with or without ALS [4–6], demonstrating a
primary, causal role for the TDP-43 protein abnormalities in
the pathogenesis of these diseases, now also termed TDP-
43 proteinopathies [7]. The function of the TDP-43 protein
remains poorly understood, but it has been initially
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characterized as a transcription factor which binds to TAR
DNA sequence motif [8] and, later, as a modulator of the
alternative mRNA splicing [9].
Several TARDBP mutations have been identified in
patients with familial and also sporadic ALS, these latter
pointing to an incomplete, age-related penetrance [10–17].
The c.G1144A substitution (predicted protein effect: p.
Ala382Thr) is the most frequent TARDBP mutation known
so far, which has been found in ALS patients of Italian and
French origins [3, 15, 16]. Very recently, the same missense
mutation was identified as the disease cause in a large
percentage (~30%) of familial and sporadic ALS patients
from Sardinia, a genetically isolated Mediterranean island
[18, 19]. Haplotype analyses in the Sardinian, Italian, and
French cases strongly suggested that this mutation origi-
nated from a common founder [15, 18, 19].
The occurrence of parkinsonism and motoneuron disease
in the same patient has sometimes been reported [20]. Of
note, three Sardinian patients with ALS who carried the
TARDBP p.Ala382Thr mutation developed parkinsonism
after the onset of the motoneuron disease [18]. However, to
our knowledge, TARDBP mutations have not been de-
scribed in patients with Parkinson’s disease (PD).
As part of an ongoing research program on the genetics
of PD in Sardinia, we therefore investigated the occurrence
of the TARDBP p.Ala382Thr mutation among patients with
this disease from this genetically isolated population. We
detected 8 out of the 327 PD cases (2.5%) who are carriers
of this mutation. Our data provide therefore a first direct
link between the TARDBP mutation and PD, supporting an
involvement of the TDP-43 protein in a broader neurode-
generative spectrum, including not only motoneuron dis-
ease and FTLD, but also PD.
Subjects and methods
All cases and controls included in the study (905 subjects)
were born and living in Sardinia, and all their four
grandparents were also born in Sardinia. The project was
approved by the relevant ethical authorities and written
informed consent was obtained from all participating
subjects.
The PD group included 327 consecutive patients (125
females, 202 males) with clinically diagnosed PD, recruited
at two movement disorder units in southern central areas of
Sardinia: the General Hospital “S. Michele” in Cagliari
(301 patients) and the S. Francesco Hospital in Nuoro (26
patients). The average onset age was 62.6 years (SD 10.5,
range 22–84). Additional clinical features are shown in
Table 1. All patients fulfilled the United Kingdom Brain
Bank Criteria for the clinical diagnosis of PD [21]. No
pathological studies were available. A detailed medical
history of the nuclear family was recorded from all the PD
cases. Patients were classified as sporadic if they reported
no other PD cases among first- and second-degree relatives.
Accordingly, there were 88 patients with familial and 239
with sporadic PD presentation. The clinical evaluation of
the parkinsonism was performed using the Hoehn-Yahr
Scale and the Unified Parkinson’s Disease Rating Scale
(UPDRS) [22]. The Mini-Mental State Examination
(MMSE) was used as a screening test for the cognitive
status.
One family with three siblings affected by different
combinations of atypical parkinsonism, FTLD, and L-dopa-
responsive parkinsonism was also ascertained and studied
(Fig. 1). A first control group consisted of 203 subjects,
age-matched to the patients (86 females, 117 males), mainly
spouses of PD cases or subjects examined at the same
centers for diseases unrelated to PD. The average age at
sampling was 71.3 years (SD 10.8, range 38–93). Among
these, 174 were collected in Cagliari and 29 in Nuoro.
Controls were eligible for inclusion only if they reported a
negative family history of PD among first- and second-
degree relatives. Moreover, at the time of the examination,
none of the controls showed any signs or symptoms of
parkinsonism, dementia, motoneuron disease or other
neurodegenerative diseases.
A second, younger group of controls was available,
consisting of 375 healthy subjects (92 females, 283 males)
ascertained within a research program on the genetics of
multiple sclerosis in Sardinia [23]. The average age at
sampling of this second control group was 42.8 years (SD
10.6, range 21–66).
Genomic DNAwas isolated from peripheral blood using
standard protocols. In the whole case–control sample, the
presence of the TARDBP c.G1144A mutation (p.Ala382Thr)
was assessed by direct DNA sequencing. In patients who
carried this mutation and in additional selected patients with
familial PD, the whole TARDBP coding region and exon–
intron boundaries was sequenced. In all cases with the
TARDBP p.Ala382Thr mutation, we also searched for the
LRRK2 p.Gly2019Ser mutation (previously reported to
occur, albeit rarely, among Sardinian PD patients) [24] by
direct sequencing, as previously described [24].
Table 1 Clinical features in the PD series
p.Ala382Thr Het carriers Non-carriers
Total no. of patients 8 319
Males 7 195
Females 1 124
Familial PD 0 88
Sporadic PD 8 231
PD onset age, years [average (SD)] 70.0 (9.4) 62.9 (10.5)
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Fragments were amplified by PCR (protocols and primers
available on request from the authors). Direct sequencing was
performed using Big Dye terminator chemistry ver.3.1
(Applied Biosystem). Fragments were loaded on an Applied
Biosystem 3130XL automated sequencer and analyzed with
DNA Sequencing analysis (ver.5.3) and SeqScape (ver.2.6)
software (Applied Biosystem). The TARDBP mutation is
numbered from the “A” of the ATG-translation initiation
codon, according to GenBank reference sequences, accession
number NM_007375.3.
Results
We identified 8 PD cases who carried the TARDBP c.
G1144A (p.Ala382Thr) variant in heterozygous state (8/
327, 2.5%) and no homozygous carriers. The detailed
clinical features in the patients who carried the p.Ala382Thr
mutation are shown in Table 2. Sequencing the whole
TARDBP coding region and exon–intron boundaries in
patients with the p.Ala382Thr mutation, as well as in five
additional patients with familial PD revealed no additional
Fig. 1 Genetic findings and neu-
roimaging in a family with FTLD
with parkinsonism and PD. a
Pedigree of the family. b Elec-
tropherogram showing the het-
erozygous TARDBP p.Ala382Thr
mutation. c DaTSCAN-SPECT
in the SAR-403 patient showing
severe defects at the level of the
caudate nucleus and putamen,
bilaterally
















Sar-006 Sporadic 86 M 79 7 RT, B, R (right) Sustained n.p. Hyposmia 24/30
Sar-053 Sporadic 65 M 51 14 RT (right) Sustained n.p. RBD 30/30
Sar-104 Sporadic 71 M 65 6 RT, B, R (right) Sustained Typical for PD RBD, hyposmia 27/30
Sar-146 Sporadic 84 M 78 6 RT, B, R (right) Sustained n.p. RBD, hyposmia 23/30
Sar-171 Sporadic 80 M 75 5 RT, B, R (right) mild
cognitive decline
+ n.p. − 18/30
Sar-220 Sporadic 91 M 71 20 B, R (right) + n.p. − 22/30
Sar-239 Sporadic 71 F 65 6 RT, B, R (right) Sustained Typical for PD RBD 29/30
Sar-579 Sporadic 81 M 76 5 RT, B, R (left) mild
cognitive decline
+ n.p. − 20/30
M male, F female, RT rest tremor, B bradykinesia, R rigidity, MMSE Mini-Mental State Examination, n.p. not performed, RBD REM-sleep
behavior disorder, + present, − absent
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novel variants. No carriers of the LRRK2 Gly2019Ser
mutation were detected.
Within the first group of controls, we identified three
subjects who also carried the p.Ala382Thr mutation in
heterozygous state and none who carried it in homozygous
state. Within the second group of controls, no mutation
carriers were detected. Our follow-up revealed that one of
the three heterozygous mutation carriers had developed
motoneuron disease at age 61, 2 years after sampling;
another developed a rapidly progressive dementia starting
approximately at age 81, 1 year after sampling, and he has
became bedridden, anarthric, and totally dependent from
caregivers’ assistance within 4 years of disease evolution.
The third subject remains free from signs or symptoms of
motoneuron disease, dementia, or parkinsonism at the age
of 79, but two of his close relatives have recently developed
motoneuron disease and dementia. If one excludes these
three control subjects who developed motoneuron disease,
or dementia, or who had close relatives with these diseases,
none of the 575 Sardinian controls in this study (1,150
chromosomes) carry the p.Ala382Thr mutation. Further-
more, in previous studies, this mutation was not detected in
more than 500 Sardinian control chromosomes [18, 19] and
in more than 1,900 Italian control chromosomes [15, 16].
None of the eight PD patients who carried the p.
Ala382Thr mutation reported any first- or second-degree
relatives affected by PD, dementia, or motoneuron disease.
They are therefore classified as sporadic PD according to
our criteria. However, information on parental age at death
was available for only six of the eight mutation carrier
probands (Table 3). Considering the late onset age of PD in
these cases and the parental age at death, censoring effects
might have masked the familial nature of the disease in at
least some of these cases. Furthermore, two patients (Sar-
006 and Sar-104) reported each one more distant relative
(first cousin) with parkinsonism. Our examination of these
distant relatives revealed in both cases a late onset, atypical
parkinsonism with poor response to levodopa, and genetic
testing revealed absence of the p.Ala382Thr mutation. We
consider these two distant relatives as phenocopies.
The eight patients who carried the p.Ala382Thr mutation
all fulfilled the UK PD Society Brain Bank criteria for a
clinical diagnosis of definite PD. Six of these display a
classical PD presentation (Table 2), while two (Sar-171 and
Sar-579) present with a postural instability–gait disturbance
predominant type of PD and also have mild cognitive
impairment and psychotic phenomena.
The average PD symptoms onset in the eight carriers of
the p.Ala382Thr mutation was 70.0±9.4 years (range 51–
79), which is later though not significantly different from
the average onset age among the patients who did not carry
this mutation (62.9±10.5 years, range 22–83, p=0.08).
Brain SPECT images (DaTSCAN) were available from two
patients with the p.Ala382Thr mutation and are shown in
Fig. 2.
Within the FTLD–parkinsonism family (Fig. 1), three
siblings were affected by different combinations of atypical
parkinsonism, FTLD, and L-dopa-responsive parkinsonism,
and they all carried the p.Ala382Thr heterozygous muta-
tion. The patients’ mother died at the age of 74 and the
father at the age of 54 (due to hepatic disease), without
evidence of neurodegenerative diseases. The proband (Sar-
403) is a 77-year-old, congenital deaf-mute woman, who
developed resting tremor and bradykinesia in her right
limbs and at the age of 76. At the moment of our
examination, after 1 year of disease course, her H-Y stage
was 1.5 and the UPDRS motor score 13. Only mild benefit
was observed after 12 months of L-dopa treatment (daily
dose of 500 mg, four times per day). Though her MMSE
was 30/30, she developed hallucinations and mild cognitive
disturbances of frontal lobe type. Brain CT scan was
unremarkable, but DaTSCAN showed severe bilateral
dopaminergic deficiency at the level of both putamen and
caudate nuclei (Fig. 1c), suggestive of an atypical parkin-
sonian disorder. Of note, evidence of motoneuron disease
was not detected after both clinical examination and EMG
investigations, after 1 year of disease course.
The proband’s brother (Sar-424) developed a rapidly
progressive, symmetrical akinetic-rigid parkinsonism with
onset at the age of 68 years, with only a mild response to L-
dopa treatment (daily dose of 600 mg, four times per day).
At the moment of our examination, after 2 years of disease
course, his H-Y stage was 4, the UPDRS motor score was
54, and the MMSE was 28/30, but he also showed severe
dementia of frontotemporal type. Frontotemporal atrophy
was also seen in his brain MRI. He died 2 years later at the
age of 72.
Interestingly, the proband’s sister (Sar-423) developed
symmetrical akinetic-rigid parkinsonism without resting
tremor at the age of 74 years. At the moment of our
examination, after 1 year of disease course, her H-Y stage
Table 3 Age at death among the parents of PD patients carrying the p.
Ala382Thr mutation
PD patient Mother Father PD onset in offspring
Sar-006 85 80 79
Sar-053 n.a. n.a. 51
Sar-104 72a 84 65
Sar-146 80 90 78
Sar-171 83 30 75
Sar-220 n.a. n.a. 71
Sar-239 64 64 65
Sar-579 87 60 76
a Referred with tremor
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was 2 and the UPDRS motor score 28. Her MMSE was 30/
30. At that time, she responded well to L-dopa treatment
and no atypical features or additional neurological signs
were observed; her clinical picture was therefore compat-
ible with a diagnosis of PD. She died 3 years later, at the
age of 78, of acute myocardial infarction.
Discussion
Genetically isolated populations are an important resource
for finding genetic determinants of human diseases. As a
result of a limited number of founder alleles, prolonged
geographical isolation, and genetic drift, the genetic
architecture of disease is expected to be simpler in the
genetic isolates than in the general populations, thereby
facilitating the identification of the disease-causing or
disease-predisposing alleles [25]. The population of Sardi-
nia is one of the most extensively studied genetic isolates,
which has yielded founder mutations and risk alleles in
several disorders ([18, 19, 23, 26] and references therein).
The recent identification of the founder TARDBP p.
Ala382Thr mutation as the cause of a large percentage of
ALS cases in this island is not only another example of the
power of this approach. It is also a proof of principle that
large etiological fractions of common neurodegenerative
diseases can be underlain by rare mutations of large effects.
A similar scenario has been delineated for the founder p.
Gly2019Ser mutation in the LRRK2 gene as a cause of PD
among patients of North African and Middle Eastern
ancestries (reviewed in [27]).
The fact that all the three apparently healthy controls
included in our study, who carried the p.Ala382Thr mutation,
have developed ALS or dementia themselves or among their
close relatives is a clear confirmation of the strong association
between this mutation and the motoneuron disease–fronto-
temporal dementia spectrum. Furthermore, one control indi-
vidual remains free from neurodegenerative signs and
symptoms at the age of 79 years, illustrating the age-related,
incomplete penetrance, already reported for this and other
TARDBP mutations. A penetrance of 60% by age 70 has
been recently estimated for the p.Ala382Thr mutation [19].
The incomplete penetrance is also in keeping with the
frequent occurrence of this founder mutation among patients
with sporadic disease presentation.
While TARDBP mutations have been detected in several
patients with familial and sporadic ALS (approximately 2–
3% of cases in large studies), to our knowledge, an
association between TARDBP mutations and FTLD has
been reported so far in only eight unrelated cases [4–6, 28,
29]. In two of these patients, the FTLD phenotype (familial
in one and sporadic in the other case) was followed by the
development of MND within 2 years [5]; in another three
cases with familial ALS (and carrying the p.Ala382Thr
mutation), the MND was the presenting phenotype, which
was followed soon by an FTLD [29]. In the remaining three
patients, sporadic FTLD presented as an isolated syndrome,
without the development of MND within the follow-up
period [4, 6, 28]. Of note, none of these cases presented
parkinsonism.
Only three of the recently reported Sardinian ALS
patients who carried the p.Ala382Thr mutation developed
akinetic parkinsonism after the onset of ALS [18].
Therefore, our family with FTLD and parkinsonism
(Fig. 1) represents already a further expansion of the
clinical spectrum associated with TARDBP mutations, by
showing two patients with FTLD and prominent parkin-
sonism without MND, and a third with pure, L-dopa-
responsive parkinsonism, in the absence of cognitive or
motoneuron disturbances.
However, the most important finding of this study is the
association between the p.Ala382Thr mutation and PD within
our consecutive large Sardinian series. This points to a broader
clinical expressivity of this mutation than earlier realized.
Fig. 2 DaTSCAN-SPECT
images in PD patients with the
TARDBP p.Ala382Thr mutation.
In two patients carrying the
TARDBP p.Ala382Thr mutation
(a Sar-239, b Sar-104), the
DaTSCAN-SPECT imaging
shows asymmetric defects,
predominantly at the level of the
putamen, as typically observed
in idiopathic PD
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To our knowledge, only one systematic study of the
entire TARDBP coding region in 125 PD patients of
French–Canadian ancestry has been published, with nega-
tive results [30]. It is interesting to note that none of our
eight PD patients who carry the mutation reported a family
history for PD, ALS, or dementia, providing further
evidence for the incomplete penetrance of this mutation.
Unfortunately, pathological studies are not available to
verify whether Lewy bodies, TDP-43-positive inclusions,
or both, are present in the brain of these patients. This
remains a very important objective for follow-up studies.
However, all these eight cases fulfill the widely accepted
clinical diagnostic criteria for definite PD, including several
supporting features (asymmetric onset, good and prolonged
L-dopa response, presence of resting tremor, progressive
course with the absence of atypical signs for more than
5 years). In two patients carrying the TARDBP p.Ala382Thr
mutation, the DaTSCAN-SPECT imaging showed asym-
metric defects, predominantly at the level of the putamen,
as typically observed in idiopathic PD (Fig. 2). Apart from
a slightly (and non-significantly) later onset age of PD
symptoms, these cases were clinically indistinguishable
from the other patients in our study.
The reasons of the broad variability in the clinical
expression of this mutation remain to be found. It is
possible that the severity and the rapid progression of the
ALS hamper the detection of extrapyramidal signs.
However, three patients who carried the p.Ala382Thr
mutation described in one of the previous studies
developed extrapyramidal symptoms several years after
their initial presentation with motoneuron disease [18].
On the other hand, it is possible that the clinical signs of
PD interfere with the detection of initial motoneuron
disease signs. Nevertheless, none of our PD mutation
carriers nor any of their close relatives developed clinical
signs of the ALS spectrum.
It is likely that additional genetic (or non-genetic) factors
modify the effects of the primary mutation (p.Ala382Thr),
thereby leading to different clinical outcomes: ALS, FTLD,
or parkinsonism, alone or in combination. For example,
patients who manifest PD, or FTLD, as the resulting
isolated clinical phenotype might carry mutations or poly-
morphisms in other loci that prevent (or delay) the onset of
motoneuron disease and lead to the appearance of extrapy-
ramidal or cognitive signs as the earliest clinical expression
of the disease. Further work remains therefore ahead to
identify the modifier(s) of this mutation, and genetic
isolates (such as the Sardinian population) represent once
more an ideal resource in this endeavor.
Following the initial association with the pathological
hallmark inclusions in patients with FTLD, ALS, and ALS-
MND, the TDP-43 protein has also been detected in the
pathological lesions in relevant percentages of brains of
patients with Lewy body disorders, ranging from 7% of PD
cases to 19% of PD with dementia in one study [31], and to
more than 50% of the brains with diffuse Lewy body
disease in another study [32]. Moreover, pathological
lesions containing the TDP-43 protein were reported in
proximity of small blood vessels in the brain of one patient
with familial Lewy body disease caused by the p.Ala53Thr
mutation in the alpha-synuclein (SNCA) gene [33]. Taken
together, these findings provide evidences of important
intersections between the pathogenesis of the TDP-43
proteinopathies and the alpha-synucleinopathies, supporting
the contention that TARDBP mutations might underlie
prominent parkinsonism in patients with FTLD and also
present as isolated PD.
In conclusion, our data provide a first direct link between
the TARDBP mutation and PD, supporting an involvement
of the TDP-43 protein in a broader neurodegenerative
spectrum, including not only motoneuron disease and
FTLD, but also PD. Further analyses of the whole TARDBP
coding region in large series of familial and sporadic PD
patients are warranted.
Acknowledgments We thank all the participating subjects for their
contribution; Dr. Francesco Cucca (Institute of Neurogenetics and
Neuropharmacology, Consiglio Nazionale delle Ricerche, Monserrato,
Sardinia) for having generously contributed DNA samples from
Sardinian control subjects; and Tom de Vries Lentsch, Erasmus MC,
Rotterdam, for the artwork. This study was supported by grants from the
“Internationaal Parkinson Fonds”—The Netherlands and the Nether-
lands Organization for Scientific Research (NWO, VIDI grant) to V.B.
Disclosure All experiments comply with the current laws of the
countries in which they were performed. The authors declare that they
have no conflict of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquiti-
nated TDP-43 in frontotemporal lobar degeneration and amyo-
trophic lateral sclerosis. Science 314:130–133
2. Sreedharan J, Blair IP, Tripathi VB et al (2008) TDP-43 mutations
in familial and sporadic amyotrophic lateral sclerosis. Science
319:1668–1672
3. Kabashi E, Valdmanis PN, Dion P et al (2008) TARDBP
mutations in individuals with sporadic and familial amyotrophic
lateral sclerosis. Nat Genet 40:572–574
4. Borroni B, Bonvicini C, Alberici A et al (2009) Mutation within
TARDBP leads to frontotemporal dementia without motor neuron
disease. Hum Mutat 30:E974–E983
5. Benajiba L, Le Ber I, Camuzat A et al (2009) TARDBP mutations
in motoneuron disease with frontotemporal lobar degeneration.
Ann Neurol 65:470–473
208 Neurogenetics (2011) 12:203–209
6. Kovacs GG, Murrell JR, Horvath S et al (2009) TARDBP
variation associated with frontotemporal dementia, supranuclear
gaze palsy, and chorea. Mov Disord 24:1843–1847
7. Geser F, Martinez-Lage M, Robinson J et al (2009) Clinical and
pathological continuum of multisystem TDP-43 proteinopathies.
Arch Neurol 66:180–189
8. Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB (1995)
Cloning and characterization of a novel cellular protein, TDP-43,
that binds to human immunodeficiency virus type 1 TAR DNA
sequence motifs. J Virol 69:3584–3596
9. Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM,
Baralle FE (2005) TDP-43 binds heterogeneous nuclear ribonu-
cleoprotein A/B through its C-terminal tail: an important region
for the inhibition of cystic fibrosis transmembrane conductance
regulator exon 9 splicing. J Biol Chem 280:37572–37584
10. Yokoseki A, Shiga A, Tan CF et al (2008) TDP-43 mutation in
familial amyotrophic lateral sclerosis. Ann Neurol 63:538–542
11. Gitcho MA, Baloh RH, Chakraverty S et al (2008) TDP-43 A315T
mutation in familial motor neuron disease. Ann Neurol 63:535–538
12. Van Deerlin VM, Leverenz JB, Bekris LM et al (2008) TARDBP
mutations in amyotrophic lateral sclerosis with TDP-43 neuropa-
thology: a genetic and histopathological analysis. Lancet Neurol
7:409–416
13. Rutherford NJ, Zhang YJ, Baker M et al (2008) Novel mutations
in TARDBP (TDP-43) in patients with familial amyotrophic
lateral sclerosis. PLoS Genet 4:e1000193
14. Kuhnlein P, Sperfeld AD, Vanmassenhove B et al (2008) Two
German kindreds with familial amyotrophic lateral sclerosis due
to TARDBP mutations. Arch Neurol 65:1185–1189
15. Corrado L, Ratti A, Gellera C et al (2009) High frequency of
TARDBP gene mutations in Italian patients with amyotrophic
lateral sclerosis. Hum Mutat 30:688–694
16. Del Bo R, Ghezzi S, Corti S et al (2009) TARDBP (TDP-43)
sequence analysis in patients with familial and sporadic ALS:
identification of two novel mutations. Eur J Neurol 16:727–732
17. Daoud H, Valdmanis PN, Kabashi E et al (2009) Contribution of
TARDBP mutations to sporadic amyotrophic lateral sclerosis. J
Med Genet 46:112–114
18. Chio A, Borghero G, Pugliatti M et al (2011) Large proportion of
amyotrophic lateral sclerosis cases in Sardinia due to a single
founder mutation of the TARDBP gene. Arch Neurol 68:594–598
19. Orru S, Manolakos E, Orru N et al (2011) High frequency of the
TARDBP p.Ala382Thr mutation in Sardinian patients with
amyotrophic lateral sclerosis. Clin Genet. doi:10.1111/j.1399-
0004.2011.01668.x
20. Qureshi AI, Wilmot G, Dihenia B, Schneider JA, Krendel DA
(1996) Motor neuron disease with parkinsonism. Arch Neurol
53:987–991
21. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of
clinical diagnosis of idiopathic Parkinson’s disease: a clinico-
pathological study of 100 cases. J Neurol Neurosurg Psychiatry
55:181–184
22. Fahn S, Elton RL, Members of the UPDRS Development
Committee (1987) Unified Parkinson’s Disease Rating Scale.
Recent developments in Parkinson’s disease. Macmillan, New
York, pp 153–163
23. Sanna S, Pitzalis M, Zoledziewska M et al (2010) Variants within
the immunoregulatory CBLB gene are associated with multiple
sclerosis. Nat Genet 42:495–497
24. Cossu G, van Doeselaar M, Deriu M et al (2007) LRRK2
mutations and Parkinson’s disease in Sardinia—a Mediterranean
genetic isolate. Parkinsonism Relat Disord 13:17–21
25. Heutink P, Oostra BA (2002) Gene finding in genetically isolated
populations. Hum Mol Genet 11:2507–2515
26. Contu D, Morelli L, Santoni F, Foster JW, Francalacci P, Cucca F
(2008) Y-chromosome based evidence for pre-neolithic origin of
the genetically homogeneous but diverse Sardinian population:
inference for association scans. PLoS One 3:e1430
27. Bonifati V (2007) LRRK2 low-penetrance mutations
(Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and
sporadic Parkinson’s disease. Neurochem Res 32:1700–1708
28. Borroni B, Archetti S, Del Bo R et al (2010) TARDBP mutations
in frontotemporal lobar degeneration: frequency, clinical features,
and disease course. Rejuvenation Res 13:509–517
29. Chio A, Calvo A, Moglia C et al (2010) Amyotrophic lateral
sclerosis-frontotemporal lobar dementia in 3 families with p.
Ala382Thr TARDBP mutations. Arch Neurol 67:1002–1009
30. Kabashi E, Daoud H, Riviere JB et al (2009) No TARDBP
mutations in a French Canadian population of patients with
Parkinson disease. Arch Neurol 66:281–282
31. Nakashima-Yasuda H, Uryu K, Robinson J et al (2007) Co-
morbidity of TDP-43 proteinopathy in Lewy body related
diseases. Acta Neuropathol 114:221–229
32. Arai T, Mackenzie IR, Hasegawa M et al (2009) Phosphorylated
TDP-43 in Alzheimer’s disease and dementia with Lewy bodies.
Acta Neuropathol 117:125–136
33. Lin WL, Castanedes-Casey M, Dickson DW (2009) Transactiva-
tion response DNA-binding protein 43 microvasculopathy in
frontotemporal degeneration and familial Lewy body disease. J
Neuropathol Exp Neurol 68:1167–1176
Neurogenetics (2011) 12:203–209 209
